AUROPHARMA — Aurobindo Pharma Balance Sheet
0.000.00%
- IN₹724.38bn
- IN₹733.49bn
- IN₹290.02bn
- 79
- 37
- 40
- 53
Annual balance sheet for Aurobindo Pharma, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
R2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 28,341 | 56,212 | 45,576 | 62,327 | 63,264 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 58,660 | 50,548 | 58,830 | 66,871 | 76,258 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 164,125 | 198,235 | 181,227 | 215,457 | 242,056 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 81,166 | 93,155 | 106,660 | 124,918 | 142,849 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 289,277 | 338,540 | 339,217 | 398,900 | 450,715 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 113,846 | 106,652 | 81,560 | 114,938 | 121,991 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 121,031 | 119,241 | 93,457 | 130,501 | 152,287 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 168,247 | 219,299 | 245,760 | 268,399 | 298,428 |
Total Liabilities & Shareholders' Equity | 289,277 | 338,540 | 339,217 | 398,900 | 450,715 |
Total Common Shares Outstanding |